Bausch Health Companies vs Viatris
Viatris is the larger business, with $14.30bn of revenue in fiscal 2025 against $10.27bn for Bausch Health Companies (1.4 times as much). Bausch Health Companies grew faster (6.7% against -3.0%). Bausch Health Companies kept more of each dollar of sales as profit: a net margin of 1.5% against -24.6%.
| Latest fiscal year | Bausch Health CompaniesBHC, 2025 | ViatrisVTRS, 2025 |
|---|---|---|
| Revenue | $10.27bn | $14.30bn |
| Revenue growth | 6.7% | -3.0% |
| Net income | $157m | −$3.51bn |
| Operating margin | 17.7% | -18.6% |
| Net margin | 1.5% | -24.6% |
| Return on equity | — | -21.1% |
| Free cash flow | $1.00bn | $1.94bn |
| Cash | $1.31bn | $1.32bn |
| Total debt | $20.82bn | $14.41bn |
| Debt to equity | — | 98.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $501m |
| Employees | 20,300 | 30,000 |
| Market value | $3.01bn | $21.83bn |
| Price vs our value range | Below our value range | Within our value range |
| Moat score | 35 (Weak) | 42 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 2 sales |